Abbvie Inc

NYSE:ABBV   3:59:59 PM EDT
-0.73 (-0.47%)
5:17:01 PM EDT: $152.71 -0.70 (-0.46%)

AbbVie Submits Application To U.S. FDA For Atogepant Label Expansion For Migraine Prevention

Published: 06/21/2022 13:47 GMT
Abbvie Inc (ABBV) - Abbvie Submits Supplemental New Drug Application to U.S. FDA for Atogepant (qulipta™) to Support Label Expansion for the Preventive Treatment of Migraine.